Crossmark

CIB1 depletion with docetaxel or TRAIL enhances triple-negative breast cancer cell death

Crossref DOI link: https://doi.org/10.1186/s12935-019-0740-2

Published Online: 2019-02-04

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Chung, Alexander H.

Leisner, Tina M.

Dardis, Gabrielle J.

Bivins, Marissa M.

Keller, Alana L.

Parise, Leslie V.
Funding

Funding for this research was provided by:

North Carolina Biotechnology Center (R41CA200189)

Graduate School, University of North Carolina at Chapel Hill
License Information

Text and Data Mining valid from 2019-02-04
More Information

Article History

Received: 20 September 2018

Accepted: 29 January 2019

First Online: 4 February 2019